SELECTIVE BORON ACCUMULATION IN HUMAN OCULAR MELANOMA VS SURROUNDING EYE COMPONENTS AFTER B-10(1)-P-BORONOPHENYLALANINE ADMINISTRATION - PREREQUISITE FOR CLINICAL-TRIAL OF NEUTRON-CAPTURE THERAPY

被引：3

作者：

WADABAYASHI, N ^{[1
]}

HONDA, C ^{[1
]}

MISHIMA, Y ^{[1
]}

ICHIHASHI, M ^{[1
]}

机构：

[1] KOBE UNIV,SCH MED,DEPT DERMATOL,7-5-2 KUSUNOKI CHO,CHUO KU,KOBE 650,JAPAN

来源：

MELANOMA RESEARCH | 1994年 / 4卷 / 03期

关键词：

B-10(1)-PARA-BORONOPHENYLALANINE; NEUTRON-CAPTURE THERAPY; MALIGNANT MELANOMA; OCULAR MELANOMA;

D O I：

10.1097/00008390-199406000-00007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We have developed neutron-capture therapy (NCT) for cutaneous malignant melanoma using a melanoma-seeking B-10-dopa, analogue, B-10(1)-para-boronophenylalanine (B-10(1)-BPA). In order to explore the feasibility of applying NCT further to ocular melanoma, we investigated the boron concentrations in ocular melanomas and normal ocular tissues by B-10(1)-BPA administration to three patients, because success of NCT depends mainly upon selective boron accumulation in melanoma. In the first and second ocular melanoma patients, to whom B-10(1)-BPA fructose complex (total dose of B-10(1)-BPA: 170 mg/kg body weight) was administered orally in two divided doses, the boron concentrations in blood, vitreous body, sclera and retina choroidea were lower than that in melanoma examined. In the third conjunctival melanoma patient, to whom B-10(1)-BPA fructose complex (dose of B-10(1)-BPA: 85 mg/kg body weight) was administered by intravenous drip infusion, the average boron concentration in four melanoma samples was 17.7 ppm, which was estimated to be within the range necessary for melanoma eradication by thermal neutron irradiation. Boron uptake by lens, vitreous body, retina choroidea and sclera was much lower than that by melanoma. It was suggested that such a superficial ocular melanoma as iris melanoma can be destroyed by NCT, although vision may be affected-mainly due to cataract formation.

引用

页码：185 / 190

页数：6

共 26 条

[1]

Mishima Y., Ichihashi M., Tsuji M., Et al., Treatment of malignant melanoma by selective thermal neutron capture using melanoma-seeking compound, J Invest Dermatol, 92, pp. 2315-3255, (1989)

[2]

Mishima Y., Ichihashi M., Hatta S., Etal. New thermal neutron capture therapy for malignant melanoma cell interaction from in vitro to first clinical trial, Pigment Cell Res, 2, pp. 226-234, (1989)

[3]

Mishima Y., Honda C., Ichihashi M., Et al., First cure of primary malignant melanoma in man by single thermal neutron capture therapy using melanoma-seeking 10B-com-pound, Lancet, 11, pp. 388-389, (1989)

[4]

Hungerford J.L., Surgical treatment of ocular melanoma, Melanoma Res, 3, pp. 305-312, (1993)

[5]

Snyder H.R., Reedy A.J., Lennarz W.J., Synthesis of aromatic boronic acids. Aldehydo boronic acids and a boronic acid analog of tyrosine, J am Chem Soc, 80, pp. 835-838, (1958)

[6]

Yoshino K., Suzuki A., Mori Y., Et al., Improvement of solubility of p-boronophenylalanine by complex formation with monosaccharides, Strahlenther Onkol, 165, pp. 127-129, (1989)

[7]

Tamat S.R., Moore D.E., Allen B.J., Determination of the concentration of complex boronated compounds in biological tissues by inductively coupled plasma atomic emission spectrometry, Pigment Cell Res, 2, pp. 281-285, (1989)

[8]

Houk R.S., Mass spectrometry of inductively coupled plasmas, Anal Chem, 58, pp. 97A-105A, (1986)

[9]

Mishima Y., Ichihashi M., Honda C., Et al., Advances in the control of human cutaneous primary and metastatic melanoma by thermal neutron capture therapy, Progress in Neutron Capture Therapy for Cancer, pp. 577-583, (1992)

[10]

Weiss J.S., Albert D.M., Intraocular melanoma, Cancer, Principle and Practice of Oncology, pp. 1423-1435, (1985)

← 1 2 3 →